Loading...
•
Sep 30, 2023
Bioatla Q3 2023 Earnings Report
Announced third quarter 2023 financial results and provided an update on its clinical programs.
Key Takeaways
BioAtla reported its Q3 2023 financial results, highlighting clinical progress with CAB-AXL-ADC (BA3011) and CAB-ROR2-ADC (BA3021), and the initiation of a Phase 2 study for CAB-CTLA-4 (BA3071). The company's cash balance is expected to fund operations into the second half of 2025.
Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study
Observed new PRs with CAB-ROR2-ADC (BA3021) Q2W dosing regimen in the Phase 2 melanoma study and a new PR with BA3021 2Q3W in the Phase 2 head and neck study
Initiated Phase 2 CAB-CTLA-4 (BA3071) study; First Patient In (FPI) completed
Cash balance of $141.3 million now expected to fund operations into 2H 2025
Forward Guidance
BioAtla expects current cash and cash equivalents will be sufficient to fund planned operations including prioritized CAB programs into second half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...